In Vivo FABP Inhibition Decreases Tumor Burden and Prolongs Survival with Multiple Myeloma
Document Type
Oral Presentation
Department
Biological Sciences
Abstract
Multiple Myeloma (MM) is the second most common type of blood cancer, with only a 53% 5-year survival rate for patients. The eventual relapse of all MM patients has led to research studying treatments that could give MM patients better outcomes and longer periods of remission. Fatty Acid Binding Protein 4 and 5 (FABP4/5) levels have been shown to be elevated in myeloma cells from patients with poor survival or shorter relapse free periods. Herein, inhibiting FABPs presents a novel approach at increasing patients’ survival. We previously demonstrated the efficacy of FABP inhibitor, BMS309403, in reducing cell number and inducing apoptosis in vitro. Now, we have demonstrated the capacity of BMS309403 to inhibit the growth in the 5TGM1-TK/KaLwRij model. The mice used were injected with MM cells through tail vein injections and then treated with 5mg/kg BMS309403 by intraperitoneal injections. Mice cohorts were monitored through bioluminescent imaging (BLI), weight change, and survival. BLI is a non-invasive method to monitor tumor burden in mice. Mice treated with BMS309403 have less tumor burden and longer survival than mice treated with a vehicle. Our findings demonstrate that FABP inhibition is a promising therapeutic in the treatment of multiple myeloma.
In Vivo FABP Inhibition Decreases Tumor Burden and Prolongs Survival with Multiple Myeloma
Multiple Myeloma (MM) is the second most common type of blood cancer, with only a 53% 5-year survival rate for patients. The eventual relapse of all MM patients has led to research studying treatments that could give MM patients better outcomes and longer periods of remission. Fatty Acid Binding Protein 4 and 5 (FABP4/5) levels have been shown to be elevated in myeloma cells from patients with poor survival or shorter relapse free periods. Herein, inhibiting FABPs presents a novel approach at increasing patients’ survival. We previously demonstrated the efficacy of FABP inhibitor, BMS309403, in reducing cell number and inducing apoptosis in vitro. Now, we have demonstrated the capacity of BMS309403 to inhibit the growth in the 5TGM1-TK/KaLwRij model. The mice used were injected with MM cells through tail vein injections and then treated with 5mg/kg BMS309403 by intraperitoneal injections. Mice cohorts were monitored through bioluminescent imaging (BLI), weight change, and survival. BLI is a non-invasive method to monitor tumor burden in mice. Mice treated with BMS309403 have less tumor burden and longer survival than mice treated with a vehicle. Our findings demonstrate that FABP inhibition is a promising therapeutic in the treatment of multiple myeloma.
